Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE). Currently, the toxicity of irAE is limiting...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepper, Alisa, Bitsch, Rebekka, Özbay Kurt, Feyza Gül, Arkhypov, Ihor, Lasser, Samantha, Utikal, Jochen, Umansky, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431726/
https://www.ncbi.nlm.nih.gov/pubmed/37593676
http://dx.doi.org/10.1080/2162402X.2023.2247303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431726/
https://www.ncbi.nlm.nih.gov/pubmed/37593676
http://dx.doi.org/10.1080/2162402X.2023.2247303

Ejemplares similares